Eluminex biosciences exclusively licenses fibrogen's biosynthetic cornea technology and recombinant collagen iii platform

Suzhou, china and san francisco, july 19, 2021 (globe newswire) -- eluminex biosciences (suzhou) limited (eluminex), an ophthalmology-focused biotechnology company headquartered in suzhou, china with a us-subsidiary office in san francisco bay area, california, announced today that it has exclusively licensed global rights for the development and commercialization of an investigational biosynthetic cornea derived from recombinant human collagen type iii intended to treat patients with corneal blindness, from fibrogen, inc. (fibrogen; nasdaq: fgen).
FGEN Ratings Summary
FGEN Quant Ranking